SLC15A1 and irritable bowel syndrome: Combined with the finding of the upregulated expression of PepT1 in IBD patients, it was suggested that 5-ASA contributes to the treatment of IBD by decreasing the uptake of bacterial peptides via PepT1 inhibition.